|
|
|
New Service
GPCR Monoclonal Antibody Profiling
|
|
Issue: There are 350 "druggable" GPCRs which share many similar primary and conformational epitopes. Is your antibody lead SPECIFIC to your GPCR target of interest?
Solution: Assess specificity of the antibody lead in Multispan's large GPCR expression panel. We measure your antibody binding to GPCRs in NATIVE conformations directly on mammalian cell surface by FACS.
Benefits: Obtain valuable information to
-make Go-Or-No-Go decision early
-save cost in expensive animal and clinical studies
-shorten lead development cycle
Convenience: Send us your purified, un-labeled antibody and you will have the results back in ONE week.
Flexibility: Choose your own panel from our 300 fully-sequenced full-length cDNAs already cloned in Multispan's powerful proprietary expression vector or use our fixed panel of 60 GPCRs below.
|

|
|
|
| Anaphylatoxin | Galanin | Melanin-Concentrating H. | Purinergic |
| C3a | GAL1 | MCH1 | P2Y2 |
| C5a | GAL2 | Melanocortin | P2Y8 |
| Apelin | Glucagon | MC4 | P2Y10 |
| APJ | glucagon | Muscarinic | P2Y12 |
| Bombesin | GPRC5 | M1 | P2Y14 |
| BB3 | GPRC5D | N-formylpeptide | Tachykinin |
| Cannabinoid | Histamine | FPR1 | NK2 |
| CB2 | H2 | Neuropeptide Y | Vasopressin/Oxytocin |
| GPR55 | Leukotriene/Lipoxin | Y1 | V2 |
| Chemokine | ALX | Neuromedin U | Orphan |
| CXCR1 | BLT1 | NMU1 | GPR18 |
| CXCR3 | BLT2 | Nicotinic Acid | GPR35 |
| CXCR4 | CysLT1 | GPR109A | GPR84 |
| CCR1 | Lysophospholipid | PAF | GPR92 |
| CCR5 | LPA1 | PAF | GPR101 |
| CCR9 | LPA2 | Prostanoid | GPR171/H963 |
| Corticortropin-releasing | LPA3 | GPR44 | MAS1 |
| CRF1 | S1P1 | FP | MRGF |
| Free Fatty Acid | S1P2 | Protease-activated | PSGR |
| FFA1 | S1P3 | PAR2 | |
| FFA2 | S1P4 | PTH | |
| FFA3 | S1P5 | PTH2 | |
|
Case Study : Identification of Multiple Cross-Reactivities of Anti-CCR5
|

|
| The N-term-tagged GPCRs are expressed in HEK293T cells. Binding of a test mAb to the GPCR receptor panel is measured by FACS analysis using Geometric Mean of fluorescence intensity. RBI (Relative Binding Index) is determined by normalizing Geometric Mean of the test mAb binding to that of anti-tag mAb binding. RBI for the test mAb to the target GPCR is set at 100%.
|
|
|